Antiviral effects of recombinant human tumor necrosis factor-alpha in combination with natural interferon-beta in mice infected with herpes simplex virus type 1

David A. Schmitt, Hidetaka Sasaki, Richard B. Pollard, Fujio Suzuki

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The protective effects of combination therapy utilizing recombinant human TNF-alpha (rTNF-α) and natural murine interferon-beta (IFN-β) in mice infected with herpes simplex virus type 1 (HSV-1) was investigated. Mice treated with rTNF-α alone at all of the doses tested (a single i.v. administration, 2.3-2,300 μg/kg; multiple i.p. administrations 0.4-250 μg/kg) as well as mice that received IFN-β alone at doses of 16 × 104 U/kg or less resulted in a 0% survival rate. Combination therapy consisting of a single administration of rTNF- α (230 and 23 μg/kg) and multiple administrations of IFN-β (4 × 104 U/kg) resulted in a 40% and 60% survival rate. Multiple treatments of infected mice with rTNF-α (50 and 10 μg/kg) in combination with IFN-β (4 × 104 U/kg) resulted in 50% and 70% survival rates, respectively. These results suggest that the combination therapy of rTNF and natural murine IFN-β produce synergistic protective effects in mice infected with a lethal amount of HSV-1.

Original languageEnglish (US)
Pages (from-to)347-352
Number of pages6
JournalAntiviral Research
Volume19
Issue number4
DOIs
StatePublished - Oct 1 1992

Fingerprint

Interferon-beta
Human Herpesvirus 1
Antiviral Agents
Tumor Necrosis Factor-alpha
Therapeutics
human TNF protein

Keywords

  • Antiviral effect
  • Human recombinant TNF-alpha
  • Natural murine IFN-beta
  • Synergism

ASJC Scopus subject areas

  • Virology
  • Pharmacology

Cite this

Antiviral effects of recombinant human tumor necrosis factor-alpha in combination with natural interferon-beta in mice infected with herpes simplex virus type 1. / Schmitt, David A.; Sasaki, Hidetaka; Pollard, Richard B.; Suzuki, Fujio.

In: Antiviral Research, Vol. 19, No. 4, 01.10.1992, p. 347-352.

Research output: Contribution to journalArticle

@article{645678b20d5d4081b62045f8117cfa3b,
title = "Antiviral effects of recombinant human tumor necrosis factor-alpha in combination with natural interferon-beta in mice infected with herpes simplex virus type 1",
abstract = "The protective effects of combination therapy utilizing recombinant human TNF-alpha (rTNF-α) and natural murine interferon-beta (IFN-β) in mice infected with herpes simplex virus type 1 (HSV-1) was investigated. Mice treated with rTNF-α alone at all of the doses tested (a single i.v. administration, 2.3-2,300 μg/kg; multiple i.p. administrations 0.4-250 μg/kg) as well as mice that received IFN-β alone at doses of 16 × 104 U/kg or less resulted in a 0{\%} survival rate. Combination therapy consisting of a single administration of rTNF- α (230 and 23 μg/kg) and multiple administrations of IFN-β (4 × 104 U/kg) resulted in a 40{\%} and 60{\%} survival rate. Multiple treatments of infected mice with rTNF-α (50 and 10 μg/kg) in combination with IFN-β (4 × 104 U/kg) resulted in 50{\%} and 70{\%} survival rates, respectively. These results suggest that the combination therapy of rTNF and natural murine IFN-β produce synergistic protective effects in mice infected with a lethal amount of HSV-1.",
keywords = "Antiviral effect, Human recombinant TNF-alpha, Natural murine IFN-beta, Synergism",
author = "Schmitt, {David A.} and Hidetaka Sasaki and Pollard, {Richard B.} and Fujio Suzuki",
year = "1992",
month = "10",
day = "1",
doi = "10.1016/0166-3542(92)90015-W",
language = "English (US)",
volume = "19",
pages = "347--352",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Antiviral effects of recombinant human tumor necrosis factor-alpha in combination with natural interferon-beta in mice infected with herpes simplex virus type 1

AU - Schmitt, David A.

AU - Sasaki, Hidetaka

AU - Pollard, Richard B.

AU - Suzuki, Fujio

PY - 1992/10/1

Y1 - 1992/10/1

N2 - The protective effects of combination therapy utilizing recombinant human TNF-alpha (rTNF-α) and natural murine interferon-beta (IFN-β) in mice infected with herpes simplex virus type 1 (HSV-1) was investigated. Mice treated with rTNF-α alone at all of the doses tested (a single i.v. administration, 2.3-2,300 μg/kg; multiple i.p. administrations 0.4-250 μg/kg) as well as mice that received IFN-β alone at doses of 16 × 104 U/kg or less resulted in a 0% survival rate. Combination therapy consisting of a single administration of rTNF- α (230 and 23 μg/kg) and multiple administrations of IFN-β (4 × 104 U/kg) resulted in a 40% and 60% survival rate. Multiple treatments of infected mice with rTNF-α (50 and 10 μg/kg) in combination with IFN-β (4 × 104 U/kg) resulted in 50% and 70% survival rates, respectively. These results suggest that the combination therapy of rTNF and natural murine IFN-β produce synergistic protective effects in mice infected with a lethal amount of HSV-1.

AB - The protective effects of combination therapy utilizing recombinant human TNF-alpha (rTNF-α) and natural murine interferon-beta (IFN-β) in mice infected with herpes simplex virus type 1 (HSV-1) was investigated. Mice treated with rTNF-α alone at all of the doses tested (a single i.v. administration, 2.3-2,300 μg/kg; multiple i.p. administrations 0.4-250 μg/kg) as well as mice that received IFN-β alone at doses of 16 × 104 U/kg or less resulted in a 0% survival rate. Combination therapy consisting of a single administration of rTNF- α (230 and 23 μg/kg) and multiple administrations of IFN-β (4 × 104 U/kg) resulted in a 40% and 60% survival rate. Multiple treatments of infected mice with rTNF-α (50 and 10 μg/kg) in combination with IFN-β (4 × 104 U/kg) resulted in 50% and 70% survival rates, respectively. These results suggest that the combination therapy of rTNF and natural murine IFN-β produce synergistic protective effects in mice infected with a lethal amount of HSV-1.

KW - Antiviral effect

KW - Human recombinant TNF-alpha

KW - Natural murine IFN-beta

KW - Synergism

UR - http://www.scopus.com/inward/record.url?scp=0026768568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026768568&partnerID=8YFLogxK

U2 - 10.1016/0166-3542(92)90015-W

DO - 10.1016/0166-3542(92)90015-W

M3 - Article

C2 - 1463323

AN - SCOPUS:0026768568

VL - 19

SP - 347

EP - 352

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 4

ER -